A systematic review published in the Journal of Cutaneous Medicine and Surgery found that patients with psoriatic arthritis (PsA) and palmoplantar psoriasis/pustular psoriasis (PPP) experience substantial psychological burden, including depression, anxiety, and sleep disturbances. The review included 17 studies and more than 76,000 patients, with available data focused only on PsA and PPP. Depression prevalence ranged from 7.1% to 41% in PsA and from 5.7% to 17.1% in PPP, while anxiety rates ranged from 5.1% to 61.4% across both conditions. Sleep disturbances affected up to 38% of patients, and mood disorders were reported in nearly 20% of PPP cases.

The findings suggest that psychological burden tends to increase with disease severity, with depression linked to a more than fourfold higher likelihood of greater disease activity. Researchers emphasized that these mental health comorbidities can worsen quality of life, contribute to functional impairment, and potentially reduce treatment adherence. However, the authors noted important limitations, including variation in study populations, diagnostic criteria, psychological assessment tools, and the mostly cross-sectional design of the evidence. They conclude that patients with PsA and PPP may benefit from more consistent mental health screening and integrated, patient-centered support as part of psoriasis care.

Reference: Steinzor P. Identifying psychological burdens in non-plaque psoriasis. AJMC. Published November 10, 2025. Accessed July 7, 2026. https://www.ajmc.com/view/identifying-psychological-burdens-in-non-plaque-psoriasis

This review summarizes the growing evidence on dietary interventions for psoriasis, emphasizing that nutrition may be a useful adjunct to standard medical treatment but should not replace proven therapies. The Mediterranean diet has the strongest overall support and the fewest downsides. Studies suggest that greater adherence may be associated with lower psoriasis activity, reduced systemic inflammation, improved cardiometabolic health, and potentially healthier gut microbiome patterns. Other approaches have shown potential benefits in selected patients, including ketogenic or very-low-calorie ketogenic diets, low-calorie diets, intermittent fasting, gluten-free diets, and vegan/vegetarian diets. These approaches may be especially relevant for patients with overweight/obesity, metabolic comorbidities, celiac disease, antigliadin antibody positivity, or interest in plant-forward eating. However, the evidence is mixed, and some benefits may be driven by weight loss rather than the diet itself.

The authors stress that dietary counseling should be individualized, realistic, and sensitive to patient interest, comorbidities, eating-disorder history, culture, access to healthy foods, and socioeconomic barriers. They caution against broadly recommending restrictive diets, food sensitivity testing, or supplements without clear evidence. For example, oral vitamin D, B12, selenium, and fish oil have insufficient or mixed support for psoriasis treatment. The review concludes that clinicians should consider diet and metabolic health as part of whole-person psoriasis care, using patient-centered conversations and practical tools, while maintaining evidence-based dermatologic therapies as the foundation of treatment.

Reference: Leung A, Kranyak A, Marquez-Grap G, Bhutani T. Nutrition and Psoriasis: The Latest Evidence and How to Approach Nutrition in Clinical Practice. Am J Clin Dermatol. 2026 Jan;27(1):9-16. doi: 10.1007/s40257-025-00992-2. Epub 2025 Dec 10. PMID: 41369865; PMCID: PMC12860837.

This analysis pooled data from bimekizumab-randomized patients in Phase 3 psoriasis trials and their open-label extension to evaluate whether complete skin clearance could be maintained long term. Among patients who achieved Psoriasis Area and Severity Index (PASI) 100 at Week 16 and continued bimekizumab treatment, 73.0% maintained PASI 100 through Year 4, while 89.6% maintained PASI 90 and 95.9% maintained PASI 75. Continuous response also was durable: 71.6% maintained “remission under treatment” through Year 4, and 91.3% maintained high disease control. In patients who stopped treatment after achieving PASI 100, median time to loss of PASI 100, PASI 90, and PASI 75 was 20, 24, and 28 weeks after withdrawal, respectively, and responses were generally regained quickly after retreatment.

The mechanistic analyses suggest that bimekizumab’s durable response may be linked to its dual inhibition of IL-17A and IL-17F and its effect on pathogenic tissue-resident memory T cells in psoriatic lesions. Transcriptomic analyses showed that bimekizumab normalized a TRM-cell gene signature and reduced expression of prosurvival factors, including IL7R, IL32, and antiapoptotic gene signatures, after treatment. The authors identified a subset of lesional TRM cells expressing IL-17A and/or IL-17F, with IL-17F-positive cells showing signals that may support longer persistence in skin. Overall, the findings support bimekizumab as a treatment capable of producing high, durable levels of skin clearance, while also offering a possible biologic explanation for why responses can remain strong over time.

Reference: Krueger JG, Cutcutache I, Lebwohl M, et al. Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability. J Allergy Clin Immunol. 2026 Jan 22:S0091-6749(26)00012-6. doi:10.1016/j.jaci.2025.12.1013. Epub 2026 Jan 22. PMID: 41580158.